Russia’s R-Pharm To Invest US$200 Million Into Kazakh Pharmaceutical Factory

Russia’s R-Pharm Group is to invest in a pharmaceutical production plant in Alatau, Kazakhstan, in partnership with the local company Khan Tengri Biopharma, according to Nikolai Zemskov, R-Pharm’s General Director of Commonwealth of Independent States (CIS) markets.

He said that “a joint venture company with an investment of US$200 million will build an innovative full-cycle biopharmaceutical hub. The project will be implemented in Alatau city, where a land plot has already been allocated.” He was speaking at the 2025 Kazakhstan Global Investment Roundtable being held in Astana.

Zemskov added that an investment agreement with the Kazakh government should be concluded, and it will be implemented within three years, he said. The products will be supplied not only to Kazakhstan’s domestic market but also for export.

R-Pharm is a Russian pharmaceutical group of companies, founded in 2001. The company has nine production sites that specialize in producing pharmaceuticals, active pharmaceutical ingredients, laboratory equipment, and medical systems, with a portfolio that includes more than 20 high-tech pharma products.